S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Americas Cardroom Keeps 1,275 Venom Fever Seats Open for Late Entry

With the Venom Fever campaign entering its second weekend, Americas Cardroom reports that over 85% of its 1,500 guaranteed tournament seats remain unclaimed. The push offers players a path into the upcoming Dual Mystery Bounty Venoms, a centerpiece of the platform’s 25th-anniversary celebrations featuring $15 million in total prize guarantees.

Americas Cardroom Keeps 1,275 Venom Fever Seats Open for Late Entry
Photo: Bio & News

The campaign, running through August 30, serves as the primary gateway to the $2,650 buy-in events scheduled for August 13. This weekend alone, the platform will distribute 60 seats across four specific qualifying tournaments. Saturday’s $55 Mega Satellite kicks off the action with five guaranteed spots, followed by a busier Sunday featuring two Mega Satellites—a $290 entry with 20 seats and a $109 event with 10—plus a $95 Beast Tournament offering 25 seats.

Players seeking lower-cost alternatives can utilize the $16.50 Venom Madness Multi-Flight satellites, where the top 15% of participants advance to Sunday finals. For those with tighter bankrolls, the site has enabled Survivor Flips starting at $0.80 and Spin to Get In opportunities as low as $0.01. The upcoming tournaments include a $12 million guaranteed No-Limit Hold'em event and a $3 million guaranteed Pot-Limit Omaha tournament, boasting top mystery bounties of $500,000 and $250,000 respectively.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!